X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
MNC pharma: Seek opportunity! - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MNC pharma: Seek opportunity!

Nov 24, 2004

According to newspaper reports, a leading consultancy firm has estimated that the Indian pharmaceutical sector will become a US$ 25 bn industry by the year 2012, up from its current levels of about US$ 6.5 bn. According to the report, while the market in India will expand, further growth will be driven by exports of pharmaceutical products. While Indian companies are likely to grab this opportunity with both the hands, in this article we have tried to understand how MNC pharma companies are poised to benefit from this opportunity by analyzing their recent performance. There are many MNC pharma companies operating in India. While some of them have really entrenched themselves in the country, others operate merely as a trading entity. Companies such as Aventis, Glaxo and Pfizer have full fledged operations in India, others like Abbott, Sanofi, Novartis are more or less trading companies.

In the chart above, we can see that these companies have shown impressive performance in terms of growth, which is more in line with the market growth rate. While the consolidated growth of these five companies in the first nine-months of 2004 is about 11%, some have outperformed the others. While MNC companies largely have shied away from introducing new products, Novartis and Aventis have taken lead in last two years by launching new products in the Indian markets even before the new patent regime is in place.

However, the new patent regime that will come into force from 2005 will be significant for these MNC pharma companies, which are preparing themselves for the same. Most of the foreign companies have restructured themselves, be it Glaxo, Pfizer or Novartis to take advantage of the new patent regime. Although, the new patent regime will come in force from 2005, we do not see any significant impact in the topline of these companies in first two years (2005 and 2006). But in the long run, these MNC companies will certainly gain market share in high value patented products.

Apart from this, the other opportunity that exists for MNC companies in India is outsourcing. Most companies in western regulated markets are facing severe price competition from the low cost generics manufactured in India. These global corporations are likely to look at cutting costs by out-sourcing their manufacturing to low cost countries such as India and presumably, the best choice for them would be their own subsidiaries. The example of this phenomenon is Aventis, which is already making bulk drugs for its parent company. In fact, 22% of Aventis revenues are from outsourcing activity. Similarly, in case of Glaxo, it is supplying drugs manufactured in India to its parent company.

Be it selling new drugs in Indian markets or supplying drugs to their parent companies in western world, Indian arms of the global pharma giants are in for a change in their growth pattern in next few years. While the markets have realised this, there are still opportunities available for long-term investors to invest in the sector's growth trajectory.


Equitymaster requests your view! Post a comment on "MNC pharma: Seek opportunity!". Click here!

2 Responses to "MNC pharma: Seek opportunity!"

d. jacob soundararaj

Feb 19, 2011

Competent & seasoned professional with over 25 years of well- honed experience in business development, marketing, channel management, team management & brand promotion in the Pharmaceutical Industry with excellent understanding of business dynamics and updated market knowledge combined with creative strategies.

Seeking a position south india based (Bangalore) covering south india

Like 

dheeman das

May 7, 2009

I am Fresher need a job in any Pharma MNC companies in any field either in market production.

Like 
  
Equitymaster requests your view! Post a comment on "MNC pharma: Seek opportunity!". Click here!

More Views on News

SHILPA MEDICARE Surges by 6%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Apr 23, 2019 | Updated on Apr 23, 2019

SHILPA MEDICARE share price has surged by 6% and its current market price is Rs 422. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index is SHILPA MEDICARE (up 5.5%). The top losers are FORTIS HEALTHCARE and UNICHEM LAB (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Apr 23, 2019 03:35 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS